To determine differences in quality of life (QOL) between patients with head and neck cancer who receive chemoradiation versus chemoradiation and neck dissection. METHODS: A prospective cohort study was conducted at two tertiary otolaryngology clinics and a Veterans Administration hospital. Sample: 103 oropharyngeal patients with Stage IV squamous cell carcinoma treated via chemoradiation Ϯ neck dissection. Intervention: self-administered health survey to collect health, demographic, and QOL information pretreatment and 1 year later. Main outcome measures: QOL via SF-36 and HNQoL. Descriptive statistics were calculated for health/clinical characteristics, demographics, and QOL scores. t tests evaluated changes in QOL over time. RESULTS: Sixty-five patients underwent chemoradiation and 38 patients underwent chemoradiation and neck dissection. Only the pain index of the SF-36 showed a significant difference between groups (P Ͻ 0.05) with the neck dissection group reporting greater pain. CONCLUSIONS: After post-treatment neck dissection, patients experience statistically significant decrement in bodily pain domain scores, but other QOL scores are similar to those of patients who underwent chemoradiation alone.
H ead and neck cancer is a devastating disease; 40,000 new cases affect Americans each year. Despite advances in understanding of the disease and changes in treatment, death rates from squamous cell carcinoma (SCCA) have fallen little over past decades. Beyond the morbidity and mortality of the disease, the treatment is itself associated with side effects. This is especially the case because of the complex integration of form and function within the head and neck. Recently the effect of treatment of these cancers on patient function and outcomes has been strongly considered. This push began with a move toward organ preservation treatment initially put forth with such studies as the VA Larynx Trial 1 and has been advanced by growing literature on quality of life (QOL) outcomes in head and neck cancer. [2] [3] [4] [5] At our treatment sites, concurrent chemoradiation has become the treatment of choice for most patients with advanced oropharyngeal SCCA. In this group, the decision of whether to perform a post-treatment neck dissection has become somewhat difficult. For patients with discrete evidence of nodal disease post-treatment, the necessity of a neck dissection is obvious. For patients without clear evidence of continued regional disease, particularly those with bulky pretreatment lymphadenopathy, there is no consensus on performing neck dissection. Our management in this setting continues to evolve, especially because of the increasing use of positron emission tomography (PET) for post-treatment surveillance.
The study of the functional and QOL implications of post-treatment neck dissection has thus become paramount. Outcomes literature indicates there are QOL implications from chemoradiation and from neck dissection, such as pain and shoulder dysfunction. The functional implications of adding a post-treatment neck dissection to chemoradiation therapy, however, have yet to be specifically considered. Hence the objective of this study is to evaluate the effect that such a neck dissection has on QOL in patients with primary oropharyngeal SCCA treated with organ preservation therapy. It is our hope that this will assist clinicians as they weigh the potential oncologic merit of neck dissection against any potential resultant changes in QOL.
METHODS
A prospective cohort study was conducted at two tertiary care centers, the University of Michigan Health System and Henry Ford Hospital, and the Ann Arbor Veterans Affairs (VA) Hospital. Patients enrolled from 2003 to the present as part of the University of Michigan Head and Neck Cancer Specialized Programs of Research Excellence (SPORE). IRB approval was obtained at all institutions. Patients with newly diagnosed oropharynx cancer were identified by treating physicians and recruited in person in a clinical setting. Only stage IV patients treated with chemoradiation were included in order to limit the sample to a more homogeneous group with advanced disease. Subjects were excluded if they did not speak English, were pregnant, were under 18, were psychologically unstable, had previous major head and neck surgery, had previous chemotherapy or radiation therapy to the head and neck (other than for lymphoma), had evidence of distant metastatic disease, did not agree to participate, or did not survive to one year. Patients who were treated with surgical resection at the primary site (11 patients), had bilateral neck dissections (two patients), or had a radical neck dissection with resection of cranial nerve (CN) XI (four patients) were also excluded. These subjects were excluded as the known increased surgical morbidity of these procedures would likely result in an altered QOL from the remainder of the patients who received neck dissections (either selective neck dissection or modified radical neck dissection sparing CN XI). All patients in the study were treated with chemoradiation therapy under several protocols for cure.
At our treating institutions, the indications for postchemoradiation neck dissection continue to evolve. During the study period, surgeons performed post-treatment neck dissections for evidence of nodal disease on clinical examination and post-treatment computed tomography (CT), as well as for new regional disease during follow-up. In addition, during the first two years of the study, surgeons performed post-treatment neck dissection for patients with evidence of 3 cm or larger pretreatment nodes. During the last year of the study, some surgeons used PET/CT at 3 or 4 months post-treatment in the setting of "complete response" to detect residual neck disease and determine if neck dissection was indicated, whereas others continued to dissect for pretreatment nodes 3 cm or larger. Selective neck dissection was the procedure of choice and was extended by surgeons to modified radical neck dissection if necessary for complete resection. Neck dissections were performed by seven head and neck oncology surgeon subspecialists, with nearly 60% of these being performed by two surgeons. Modified radical neck dissections were performed in the standard fashion, and selective neck dissections included nodal groups described by Medina. 6 All selective neck dissections included at least levels II and III, but not level V. Although the surgeons who took part in the study all maintain a similar approach to neck dissection, there remains inherent heterogeneity within the surgical group. More information on levels and structures dissected as well as surgeons performing dissection can be seen in Table 1 .
Participating subjects completed a self-administered health questionnaire. Research assistants helped facilitate recruitment and data collection. Subjects signed a consent document prior to participation and required approximately 20 minutes to complete the survey. Participants were compensated with $10.
The self-administered survey collected data on clinical and outcomes measures. The primary measures of QOL were the SF-36 and the HNQoL (Head and Neck Quality of Life Instrument) ( Table 2 ). The SF-36 is a validated general measure used to assess social, physical, role, and emotional functioning. 7 Disease specific QOL outcomes were measured with the HNQoL instrument. This tool uses 20 items to investigate the four domains of communication, emotional well-being, head and neck pain, and eating and swallowing. 8 These instruments are well described in the literature.
The survey also collected data on health behaviors, depressive symptoms, and demographics, including age, gender, race, education, and marital status. A medical record review was conducted to collect clinical information including cancer subsite, cancer stage, comorbidities, and treatment received. As the large majority of the subjects in the study are considered white, race was designated as white (non-Hispanic) and nonwhite. Other clinical characteristics collected included tracheostomy status, disabled status, and mean BMI. Disabled status was determined by evaluating if patients were actively working before being diagnosed with cancer and, in this case, were then told by their physicians that they were not able to work secondary to their cancer. Depression was evaluated via the Geriatric Depression Scale-Short Form (GDS-SF) in which probable depression is indicated by a score of four or above. Alcohol abuse was investigated via the Alcohol Use Disorder Identification Test (AUDIT). This tool uses 10 items to delineate alcoholrelated difficulties with a score of eight or above. Answering yes to smoking within the last month designated a patient as a smoker.
Data points were recorded at baseline and one year. For continuous variables analysis was conducted on the change in score from baseline to one year. Descriptive statistics (means or frequency distributions) were computed for all variables. Bivariate analyses using t tests, 2 , and Fisher's exact tests compared the two treatment groups on age, gender, race, marital status, education level, comorbidities, hospital site, and specific tumor site within the oropharynx. Paired t tests and the sign test were used to detect changes within groups from baseline to one year. t tests were used to compare the change in scores for differences between treatment groups. Because this is a pilot study, no multiple test corrections were used. The data were analyzed with SAS (SAS Institute, Inc, Cary, NC). Values for P Ͻ 0.05 were considered statistically significant. The funding source had no role in study design.
RESULTS
Of 103 study patients, 65 received chemoradiation alone and 38 required chemoradiation and neck dissection. De-mographic and clinical information can be seen in Table 1 . The majority of patients were treated at the University of Michigan. Both treatment groups were largely composed of white males in their fifties and were relatively well-balanced with respect to age, gender, race, education level, comorbidity, and marital status.
There were no statistically significant differences in the baseline characteristics of the treatment groups other than N3 status. There were 8 (12%) N3 patients in the chemoradiation alone group and 12 (32%) in the neck dissection group, and this difference was statistically significant by Fisher's exact test (P ϭ 0.03). Other T and N designations were equally represented in both groups. Most patients had primary cancers of the tonsil (largest group) and base of tongue. Subsites were almost equally represented between those that required neck dissection and those that did not ( Table 1) .
The chemoradiation/post-treatment neck dissection group included 38 patients with the neck dissections split nearly evenly between selective (n ϭ 22, 58%) and modified radical (n ϭ 16, 42%). Differences in QOL measures were calculated within each individual treatment group over the one-year time interval (Table 3 ). Mean baseline QOL scores were very similar between the testing groups with all mean domain scores on the SF-36 and the HNQOL falling within 0.2 to 6.9 points of each other. When compared with U.S. population norms, 7 all mean scores recorded for the SF-36 at baseline and one year later fall below the national average. This is true for both treatment groups with the exception of the mental health score for the chemoradiation alone group at one-year follow-up, which is equal to the population norm at 74.7.
For the QOL measures within each treatment group, some had changes from baseline to one year that were significant. Those treated with chemoradiation alone experienced a significant improvement in the pain (P Ͻ 0.01) and mental health (P Ͻ 0.05) domains of the SF-36 as well as the emotional distress domain of the HNQoL (P Ͻ 0.01). For patients with added neck dissection, they also experienced a statistically significant improvement in the mental health domain of the SF-36 and emotional distress domain of the HNQoL (both P Ͻ 0.05). This group, however, had a decrease in the pain domain of the SF-36 that was not statistically significant. Both treatment groups experienced a significant decline in the physical function domain of the SF-36 (P Ͻ 0.05) and in the eating domain on the HNQoL (P Ͻ 0.01).
Changes in clinical characteristics were also evident from baseline to one year. No patients required tracheostomy. Both treatment groups had a significant improvement in depression scores from baseline to one year (P Ͻ 0.01). In addition, both groups had significant improvement in rates of smoking (P Ͻ 0.01) and alcohol use (P Ͻ 0.05) from baseline to one year. BMI decreased in a significant manner from baseline to one year for both groups (P Ͻ 0.01). Table 4A compares how much change in QOL each treatment group experienced from baseline to one year. Only the bodily pain index of the SF-36 showed a significant difference between groups. The postchemoradiation neck dissection group experienced more pain (P ϭ 0.041); however, this did not manifest on the HNQoL pain domain. No other domains within the SF-36 or HNQoL showed a significant difference between the two groups. Table 4B compares changes in QOL from baseline to one year within the neck dissection group (selective neck dissection versus modified radical neck dissection). Only in the mental health domain of the SF-36 did these groups have a significant difference; the selective neck dissection experienced an improvement in mental health scores whereas the modified radical group had a small decline.
Although the HNQoL pain domain as a whole did not show a significant difference between treatment groups, the pain domain scores of the HNQoL were then evaluated individually to determine if any of the individual items of this domain were different between groups. This post-hoc analysis evaluated changes within each group from baseline to one year as well as for differences between the two treatment groups ( Table 5 ). As seen in Table 5A , both groups experienced a statistically significant improvement in the amount of pain medication taken from baseline to one year. As seen in Table 5b , when the change from baseline to one year was compared between treatment groups, one aspect of the HNQoL pain domain-the shoulder/neck pain score-showed the neck dissection group having a greater decline in shoulder and neck pain scores from baseline to year one. However, this was not significant (P ϭ 0.06).
DISCUSSION
As the debate continues with respect to the oncologic merits of post-treatment neck dissection, the consideration of the effects of neck dissection on QOL is essential. This study is the first to show that other than pain, there were no differences in QOL scores between Stage IV oropharyngeal cancer patients treated with chemoradiation versus chemoradiation and neck dissection. The evidence of greater pain in the neck dissection group is consistent with the literature on the effects of neck dissection on QOL. In the early years of this surgery, a shoulder syndrome was recognized, 9, 10 and the handicaps associated with radical neck dissection and resection of CN XI were documented. 11 More recently, new measures have been developed to evaluate QOL and function after neck dissection, and the evidence has grown to document the effects of this surgery. Terrell et al 12 found neck dissection was associated with decrement in QOL in physical functioning domains. More limited (selective) neck dissections cause less pain and decrement in QOL, whereas sparing CN XI and avoiding dissection of level V likewise have positive effects. [13] [14] [15] [16] [17] Chepeha et al 15 found that functional results after neck dissection were influenced positively by increased patient weight and negatively by radiation.
As no study to date has specifically evaluated patients who undergo neck dissection after chemoradiation, the finding of greater pain in the neck dissection group is important. This study was completed within a single stage and site of the head and neck to remove the possibility of deficit variation secondary to site of primary and treatment required (ie, radiation field). It is interesting however, that the difference between the treatment groups did not manifest in all portions of the evaluation relating to pain. Importantly, there was no difference in the HNQoL pain domain. As this measure is more specific to head-and neck-related pain, this suggests that the difference in pain between groups is likely small. Likewise, it is important that no other differences of significance were appreciated in the other quality of life domains evaluated. Further follow-up in this patient population will determine if differences in pain scores will remain in the long term or scores will become more similar over time.
At baseline, both study groups were quite similar in clinical characteristics and QOL scores. After undergoing treatment, both treatment groups experienced changes in their QOL. Notably, within each treatment group, patients experienced a significant improvement in the mental health and emotional distress domains, and depression decreased in both groups. This is consistent with previous literature with similar follow-up, with improvement of mental health scores over time after treatment, but not during initial treatment for cure. [18] [19] [20] Most likely this results from improved patient outlook after survival to one year. Both treatment groups also showed a significant decline in physical function and eating domains from baseline to one year, which is consistent both with clinical experience and previous literature. Not surprisingly, on nearly all domains of the SF-36, our patients' QOL scores at baseline and one year were below the national average, reinforcing the significant impact of oropharyngeal SCCA.
Both patient groups experienced significant change in some clinical characteristics from baseline to one year. Alcohol and tobacco use decreased in both groups as has been shown in previous literature. These behaviors are interrelated; Duffy et al 21 have shown that smokers are more likely to be problem drinkers and problem drinkers are more likely to be smokers. One must consider, however, the exclusion of those patients who did not survive past one year who potentially continued to use alcohol and tobacco.
Finally, one must consider limitations of the study. The sample size was small, and there were more subjects in the chemoradiation alone group. In addition, the neck dissection group has inherent heterogeneities. All pretreatment characteristics were similar at baseline with the exception of N3 status that was significant. Inherent to the question being asked by the study, there was a larger percentage of neck dissection patients that were N3, as patients with bulky nodal disease are more likely to require post-treatment neck dissection. As such, more aggressive nodal disease could potentially be the cause of greater pain in this group. Finally, patients who died before completing one year followup, who did not agree to participate, or who were lost to follow-up were excluded from the study, and such patients may have had different QOL experiences.
Thus, in our study, patients who underwent postchemoradiation neck dissection did not experience vastly different QOL than their counterparts who did not undergo neck dissection. Significant differences in the SF-36 pain domain are not surprising given the literature on the effects of neck dissection on pain, shoulder function, and QOL. It is notable, however, that there were no other significant differences in change of QOL between the two groups.
CONCLUSION
Concurrent chemoradiation has become the standard of care at many institutions to treat several sites of head and neck cancer. The decision as to when to perform a post-treatment neck dissection for oncologic reasons is complex. Large pretreatment cervical nodal disease has shown increasing rates of "complete response" to therapy, and the optimum use of PET for surveillance of the post-treatment neck is yet to be definitively determined. The addition of QOL information to this clinical decision-making process is helpful. In this case, post-treatment neck dissection after chemoradiation significantly affected patient QOL only in the Bodily Pain domain of the SF-36 and thus was not consistent across all pain domains tested. As no other differences emerged, our impression is that in patients treated for cure with chemoradiation, post-treatment neck dissection adds some decrement in patient QOL but should be performed when oncologically indicated.
